- €13.07bn
- €12.06bn
- €3.93bn
Brief: Ipsen: EC Conditional Marketing Authorization For Ojemda (Tovorafenib)
Brief: Ipsen Says Beech Tree Obtained French Regulator Exemption On Public Tender Offer
Europe Research Roundup: HBX Group, Ipsen, Knorr Bremse
Brief: Ipsen Appoints Michelle C. Werner As EVP, President Of North America
Brief: HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
Ipsen shares slip after cancer drug Tazverik withdrawal
Brief: Ipsen Withdraws Tazverik® (tazemetostat) In Follicular Lymphoma, Epithelioid Sarcoma
Brief: Ipsen Receives Positive CHMP Opinion For Ojemda
Ipsen shares rise driven by FY results beat
France's Ipsen FY 2025 revenue misses expectations
Brief: Ipsen FY Revenue EUR 3,675.9 Million
French and Benelux stocks-Factors to watch
France rejects Trump's comment on drug prices, calls it 'fake news'
Brief: IPSEN: Arbitration Tribunal Upholds Ipsen's Termination Of Research And Development Agreement With Galderma
Brief: Ipsen Says 45.7% Spasticity Rate In Stroke Survivors In EPITOME Trial
Brief: Ipsen Says U.S. FDA Grants Ipsen’s IPN60340 Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
Top of the Street: Ipsen, Carnival, consumer goods, REITs, oil
UBS cuts Ipsen to 'neutral' as Cabometyx patent cliff looms